<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618601</url>
  </required_header>
  <id_info>
    <org_study_id>15606</org_study_id>
    <nct_id>NCT04618601</nct_id>
  </id_info>
  <brief_title>Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure</brief_title>
  <acronym>DANAUS-AHF</acronym>
  <official_title>Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laikο General Hospital, Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laikο General Hospital, Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-center, open-label and randomized trial for evaluation of the&#xD;
      effect of a 5-day administration of high doses of spironolactone (≥100mg daily) on diuresis,&#xD;
      natriuresis, weight loss and levels of NT-proBNP in hospitalized patients with acute&#xD;
      decompensated heart failure (ADHF). Mineralocorticoid receptor antagonists (MRAs) are&#xD;
      recommended as standard of care (SOC) in management of heart failure (HF) patients. However,&#xD;
      recommended doses of MRAs (up to 50mg daily) have any impact on signs and symptoms of volume&#xD;
      overload. Therefore, the proposed study will aim to show the impact of high doses of&#xD;
      spironolactone to improve diuresis, natriuresis, weight loss and levels of NT-proBNP in&#xD;
      hospitalized patients with ADHF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Congestion represents a hallmark feature of ADHF, which is present in more than 90% of&#xD;
      patients hospitalized for this diagnosis. Intravenous loop diuretics are the mainstay of&#xD;
      treatment. Nonetheless, nearly half of the patients who are hospitalized for AdHF continue to&#xD;
      have residual symptoms and sign of congestion at time of discharge. Various pharmacological&#xD;
      and non-pharmacological interventions have been proposed over the past years as potential&#xD;
      means for relieving congestion in hospitalized ADHF patients. However, their efficacy has not&#xD;
      been shown.&#xD;
&#xD;
      Given that hyperaldosteronism is a key feature in HF, the hypothesis that administration of&#xD;
      high doses of spironolactone can potentiate the natriuretic effects of loop diuretics and&#xD;
      relieve congestion in the setting of ADHF has been raised.&#xD;
&#xD;
      According to the most recent guidelines spironolactone can be considered in combination with&#xD;
      loop diuretic in patients with resistant edema or insufficient symptomatic response. However,&#xD;
      spironolactone at a dose of 100 mg daily has failed to increase diuresis in patients with&#xD;
      ADHF.&#xD;
&#xD;
      The present study will assess the effect of high per os doses of spironolactone (≥100mg) on&#xD;
      top of SOC treatment compared with SOC treatment alone on diuresis, natriuresis, weight loss&#xD;
      and levels of NT-proBNP in hospitalized patients with ADHF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daily urine output</measure>
    <time_frame>5 days</time_frame>
    <description>Urine output in liters per 24 hours will be tracked from enrollment to day 5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total urine output</measure>
    <time_frame>5 days</time_frame>
    <description>Urine output in total liters from enrollment to day 5 will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total weight change</measure>
    <time_frame>5 days</time_frame>
    <description>Patient weight in kilos will be tracked from enrollment to day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily weight change</measure>
    <time_frame>5 days</time_frame>
    <description>Patient weight in kilos will be tracked from enrollment to day 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natriuresis on days 1, 3 and 5</measure>
    <time_frame>5 days</time_frame>
    <description>Urine sodium will be measured on days 1, 3 and 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in natriuresis between days 1, 3 and 5</measure>
    <time_frame>5 days</time_frame>
    <description>Urine sodium will be measured on days 1, 3 and 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NT-proBNP between days 1 and 5</measure>
    <time_frame>5 days</time_frame>
    <description>NT-proBNP will be measured on days 1, 3 and 5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure Acute</condition>
  <condition>Heart Failure; With Decompensation</condition>
  <arm_group>
    <arm_group_label>High-dose spironolactone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will receive high doses of per os spironolactone, defined as doses ≥100 mg daily, on top of standard of care treatment for acute heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this arm will standard of care treatment for acute heart failure, which may include per os spironolactone at a maximum dose of 50 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>Patients randomized to the high-dose spironolactone group will receive oral spironolactone (≥100 mg) on top of standard of care treatment for acute heart failure immediately after randomization and in the afternoon of each subsequent day unless the serum potassium level is &gt;5 mmol/L. The exact dose will be determined based on a pre-specified algorithm provided.</description>
    <arm_group_label>High-dose spironolactone</arm_group_label>
    <other_name>Aldactone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of acute heart failure within the past 8 hours&#xD;
&#xD;
          -  Two of the following: 1. edema, 2. ascites, 3. jugular vein distention, 4. pulmonary&#xD;
             congestion&#xD;
&#xD;
          -  NT-proBNP &gt;1,000 pg/ml or &gt;3,000 pg/ml (in the presence of atrial fibrillation)&#xD;
&#xD;
          -  Per os mean daily loop diuretic dose equivalent to 80 mg of furosemide for at least 1&#xD;
             month prior to presentation and at least one of the following: 1. serum urea/serum&#xD;
             creatinine &gt; 50 at presentation, 2. serum creatinine increased &gt;0.3 mg/dl compared&#xD;
             with previous value (within the last year), 3. serum creatinine &gt; 1.8 mg/dl.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  current acute coronary syndrome&#xD;
&#xD;
          -  significant valvular disease&#xD;
&#xD;
          -  pulmonary embolism&#xD;
&#xD;
          -  allergy or intolerance to spironolactone&#xD;
&#xD;
          -  current mechanical circulatory support&#xD;
&#xD;
          -  primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy&#xD;
&#xD;
          -  mean arterial pressure &lt;65mmHg or systolic arterial pressure &lt;90 mmHg at presentation&#xD;
&#xD;
          -  anticipated use of inotropes or vasodilators (other than renal doses of dopamine, i.e.&#xD;
             &lt;2.5 μg/kg/min)&#xD;
&#xD;
          -  anticipated need of ultrafiltration&#xD;
&#xD;
          -  exposure to nephrotoxic agents within 3 days of presentation&#xD;
&#xD;
          -  serum potassium&gt; 5 mmol/L&#xD;
&#xD;
          -  per os receipt of spironolactone or eplerenone in a dose &gt; 50 mg daily prior to&#xD;
             presentation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Barbetseas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Laikon General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laiko General Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Kapelios CJ, Bonou M, Vogiatzi P, Tzanis G, Mantzouratou P, Lund LH, Barbetseas J. Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study. Am J Cardiovasc Drugs. 2018 Oct;18(5):415-422. doi: 10.1007/s40256-018-0290-3.</citation>
    <PMID>29971596</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laikο General Hospital, Athens</investigator_affiliation>
    <investigator_full_name>Chris Kapelios</investigator_full_name>
    <investigator_title>Cardiology Fellow</investigator_title>
  </responsible_party>
  <keyword>diuretic resistance</keyword>
  <keyword>spironolactone</keyword>
  <keyword>cardio-renal syndrome</keyword>
  <keyword>diuretics</keyword>
  <keyword>natriuresis</keyword>
  <keyword>heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The individual participant data of the study will be shared on reasonable request to the principle investigator</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

